Haleon (HLN) Net Cash Flow (2021 - 2025)

Haleon's (HLN) quarterly Net Cash Flow came in at -$3.5 billion in Q4 2025, down 223.22% on a QoQ basis from -$1.1 billion in Q4 2023.

Haleon (HLN) Net Cash Flow (2021 - 2025) Analysis & Trends

Haleon (HLN) has 4 years of Net Cash Flow data on file, last reported at -$3.5 billion in Q4 2025.

Quarterly Net Cash Flow changed N/A year-over-year to -$3.5 billion in Q4 2025, while the trailing twelve-month figure through Jun 2026 was -$3.5 billion (changed N/A YoY) and the FY2025 annual result came in at -$1.1 billion, down 168.86% from the prior year.
Net Cash Flow fell to -$3.5 billion in Q4 2025, from -$1.1 billion in the prior quarter.
In the past five years, Net Cash Flow ranged from a high of -$341.0 million in Q4 2021 to a low of -$11.4 billion in Q3 2022.
A 4-year average of -$5.4 billion and a median of -$3.5 billion in 2025 frame the typical range for Net Cash Flow.
Annual changes were most pronounced in 2022 — Net Cash Flow tumbled 3081.95% — and 2023, when it surged 90.1%.
Tracing HLN's Net Cash Flow over 4 years: stood at -$341.0 million in 2021, then plunged by 3081.95% to -$10.9 billion in 2022, then surged by 90.1% to -$1.1 billion in 2023, then sank by 223.22% to -$3.5 billion in 2025.
The last three Net Cash Flow figures came in at -$3.5 billion (Q4 2025), -$1.1 billion (Q4 2023), and -$10.9 billion (Q4 2022), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Cash Flow (Qtr)
1	Haleon	44.51 Bn	43.55 Bn	-	-
2	Teva Pharmaceutical Industries	43.52 Bn	39.86 Bn	2.15 Bn	-81.00 Mn
3	Zoetis	32.43 Bn	30.75 Bn	1.05 Bn	-458.00 Mn
4	Takeda Pharmaceutical	28.63 Bn	22.83 Bn	5.10 Bn	-881.03 Mn
5	United Therapeutics	21.87 Bn	19.21 Bn	683.80 Mn	523.50 Mn
6	Viatris	18.98 Bn	18.09 Bn	1.46 Bn	-912.40 Mn
7	Neurocrine Biosciences	15.43 Bn	15.04 Bn	935.80 Mn	64.40 Mn
8	Elanco Animal Health	12.02 Bn	11.49 Bn	798.00 Mn	93.00 Mn
9	Dr Reddys Laboratories	10.14 Bn	9.98 Bn	-	-
10	Alkermes	8.07 Bn	7.41 Bn	397.90 Mn	159.98 Mn

Download Data